Centessa Pharmaceuticals (CNTA) Financials

$39.60 -0.07 (-0.18%)

Closing price 04:00 PM Eastern

Extended Trading

$40.50 +0.90 (+2.27%)

As of 07:27 PM Eastern

Annual Income Statements for Centessa Pharmaceuticals

This table shows Centessa Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-5.06	-11	-218	-148	-233	-199
Consolidated Net Income / (Loss)	-5.06	-11	-216	-151	-236	-198
Net Income / (Loss) Continuing Operations	-5.06	-11	-216	-151	-236	-198
Total Pre-Tax Income	-5.06	-11	-217	-176	-233	-196
Total Operating Income	-5.05	-10	-212	-171	-201	-208
Total Gross Profit	0.00	0.00	0.00	6.85	0.00	15
Total Revenue	0.00	0.00	0.00	6.85	0.00	15
Operating Revenue	-	-	0.00	6.85	0.00	15
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	5.05	10	210	178	201	223
Selling, General & Admin Expense	0.79	1.14	55	54	51	50
Research & Development Expense	4.26	9.30	155	124	150	172
Total Other Income / (Expense), net	-0.01	-0.22	-4.69	-4.86	-32	12
Interest Expense	0.12	0.31	7.28	9.91	44	11
Interest & Investment Income	0.01	-0.07	0.24	10	14	21
Other Income / (Expense), net	0.11	0.16	2.34	-5.43	-1.69	2.91
Income Tax Expense	0.00	0.00	-0.75	-25	2.84	1.82
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	-	-	2.19	-5.98	-6.73	0.21
Basic Earnings per Share	$0.00	$0.00	($2.31)	($1.57)	($2.06)	($1.46)
Weighted Average Basic Shares Outstanding	0.00	0.00	93.40M	96.18M	114.47M	135.72M
Diluted Earnings per Share	$0.00	$0.00	($2.31)	($1.57)	($2.06)	($1.46)
Weighted Average Diluted Shares Outstanding	0.00	0.00	93.40M	96.18M	114.47M	135.72M
Weighted Average Basic & Diluted Shares Outstanding	-	-	94.96M	100.31M	133.18M	154.57M

This table shows Centessa Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-23	-39	-36	-38	-44	-42	-109	-28	-51	-54	-66
Consolidated Net Income / (Loss)	-25	-39	-37	-38	-44	-43	-111	-26	-50	-55	-66
Net Income / (Loss) Continuing Operations	-25	-39	-37	-38	-44	-43	-111	-26	-50	-55	-66
Total Pre-Tax Income	-49	-41	-36	-38	-43	-42	-110	-25	-50	-55	-67
Total Operating Income	-47	-40	-35	-36	-44	-46	-75	-31	-55	-54	-68
Total Operating Expenses	47	40	42	36	44	46	75	46	55	54	68
Selling, General & Admin Expense	13	12	12	13	11	13	14	12	12	12	14
Research & Development Expense	34	28	30	23	33	34	61	33	43	42	54
Total Other Income / (Expense), net	-1.92	-1.27	-0.52	-1.48	0.87	4.45	-36	6.04	5.09	-0.94	1.79
Interest Expense	2.45	2.54	2.57	2.53	2.53	2.56	37	2.88	2.88	2.89	2.81
Interest & Investment Income	2.06	2.95	2.93	2.59	3.24	3.34	4.85	7.89	4.38	3.77	4.49
Other Income / (Expense), net	-1.53	-1.68	-0.88	-1.54	0.15	3.66	-3.97	1.03	3.59	-1.81	0.10
Income Tax Expense	-24	-2.83	1.14	0.48	0.71	0.61	1.05	1.40	0.78	0.17	-0.52
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	-0.78	0.33	-3.74	-0.26	0.06	-1.00	-4.24	4.28	0.97	-2.02	-3.02
Basic Earnings per Share	($0.26)	($0.40)	($0.38)	($0.38)	($0.40)	($0.37)	($0.91)	($0.20)	($0.38)	($0.41)	($0.47)
Weighted Average Basic Shares Outstanding	95.16M	96.65M	96.18M	99.89M	109.49M	116.25M	114.47M	133.03M	133.68M	134.16M	135.72M
Diluted Earnings per Share	($0.26)	($0.40)	($0.38)	($0.38)	($0.40)	($0.37)	($0.91)	($0.20)	($0.38)	($0.41)	($0.47)
Weighted Average Diluted Shares Outstanding	95.16M	96.65M	96.18M	99.89M	109.49M	116.25M	114.47M	133.03M	133.68M	134.16M	135.72M
Weighted Average Basic & Diluted Shares Outstanding	97.40M	97.63M	100.31M	113.04M	113.31M	131.85M	133.18M	133.62M	134.07M	134.45M	154.57M

This table details how cash moves in and out of Centessa Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2019	2020	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	3.70	-9.34	-201	-266	255	-321
Net Cash From Operating Activities	-5.83	-11	-201	-160	-142	-194
Net Cash From Continuing Operating Activities	-5.83	-11	-201	-160	-142	-194
Net Income / (Loss) Continuing Operations	-5.06	-11	-216	-151	-236	-198
Consolidated Net Income / (Loss)	-5.06	-11	-216	-151	-236	-198
Depreciation Expense	0.01	0.00	0.13	0.81	0.94	0.92
Amortization Expense	-	-	-	-	0.00	1.16
Non-Cash Adjustments To Reconcile Net Income	0.24	0.52	21	33	68	29
Changes in Operating Assets and Liabilities, net	-1.01	-0.49	-5.52	-43	25	-28
Net Cash From Investing Activities	0.00	0.00	-0.93	-127	31	-419
Net Cash From Continuing Investing Activities	0.00	0.00	-0.93	-127	31	-419
Purchase of Property, Plant & Equipment	0.00	0.00	-1.14	-0.17	-0.03	-0.37
Purchase of Investments	-	-	0.00	-265	-141	-740
Sale and/or Maturity of Investments	-	-	0.00	138	172	322
Net Cash From Financing Activities	9.01	1.36	0.46	21	365	292
Net Cash From Continuing Financing Activities	9.01	1.36	0.46	21	365	292
Repayment of Debt	0.00	0.00	-0.26	0.00	-110	-0.40
Issuance of Debt	3.84	1.36	-	0.00	109	0.00
Issuance of Common Equity	0.00	0.00	0.00	21	360	275
Other Financing Activities, net	0.00	0.00	0.72	0.31	5.91	17
Effect of Exchange Rate Changes	0.52	-0.08	-0.42	0.62	1.23	-0.45
Cash Interest Paid	0.00	0.00	7.28	9.91	10	9.46
Cash Income Taxes Paid	-	-	1.30	2.94	0.08	1.33

This table details how cash moves in and out of Centessa Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Net Change in Cash & Equivalents	-115	26	-43	-9.81	9.15	268	-12	-278	-61	6.57	11
Net Cash From Operating Activities	-44	-37	-31	-37	-41	-21	-43	-57	-22	-58	-56
Net Cash From Continuing Operating Activities	-44	-37	-31	-37	-41	-21	-43	-57	-22	-58	-56
Net Income / (Loss) Continuing Operations	-25	-39	-37	-38	-44	-43	-111	-26	-50	-55	-66
Consolidated Net Income / (Loss)	-25	-39	-37	-38	-44	-43	-111	-26	-50	-55	-66
Depreciation Expense	0.24	0.24	0.25	0.24	0.24	0.24	0.23	0.22	0.23	0.24	0.24
Amortization Expense	-	-	-	0.00	-	-	-	0.31	0.29	0.27	0.28
Non-Cash Adjustments To Reconcile Net Income	6.82	8.39	9.22	9.33	8.39	7.73	43	5.87	7.96	7.14	8.45
Changes in Operating Assets and Liabilities, net	-26	-7.37	-3.67	-8.81	-5.39	13	26	-38	19	-11	1.39
Net Cash From Investing Activities	-71	49	-18	17	-55	45	25	-222	-40	62	-218
Net Cash From Continuing Investing Activities	-71	49	-18	17	-55	45	25	-222	-40	62	-218
Purchase of Property, Plant & Equipment	-0.01	-0.04	-0.03	-	-	-0.03	-	-	-	-0.23	-0.01
Purchase of Investments	-71	-37	-70	-20	-121	-	-	-297	-83	-46	-314
Sale and/or Maturity of Investments	-	86	52	37	65	45	25	75	43	108	96
Net Cash From Financing Activities	0.01	15	6.36	10	105	246	2.96	3.09	1.61	3.44	283
Net Cash From Continuing Financing Activities	0.01	15	6.36	10	105	246	2.96	3.09	1.61	3.44	283
Repayment of Debt	-	-	-	0.00	-	-0.97	-112	-4.79	4.39	-	-0.01
Issuance of Common Equity	-	15	6.24	9.66	107	243	-0.03	6.11	-	-	269
Other Financing Activities, net	0.01	0.18	0.12	0.84	0.80	4.25	5.34	1.76	-2.79	3.44	14
Effect of Exchange Rate Changes	0.38	0.22	-0.50	0.22	-0.12	-1.90	3.03	-1.52	-0.11	-0.50	1.68
Cash Interest Paid	2.45	2.54	2.57	2.53	2.52	2.56	2.47	1.68	2.62	2.62	2.54
Cash Income Taxes Paid	2.57	0.24	-0.00	0.00	0.00	0.01	0.07	0.00	0.99	0.11	0.23

This table presents Centessa Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	12	630	444	360	577	687
Total Current Assets	11	629	438	315	536	368
Cash & Equivalents	7.23	595	394	128	383	61
Short-Term Investments	-	-	-	129	99	233
Prepaid Expenses	1.31	18	20	21	10	19
Current Deferred & Refundable Income Taxes	2.63	15	24	38	44	54
Plant, Property, & Equipment, net	0.00	0.16	1.17	1.04	0.74	0.81
Total Noncurrent Assets	0.55	0.70	1.88	44	40	319
Long-Term Investments	-	-	-	-	0.00	283
Noncurrent Deferred & Refundable Income Taxes	-	-	-	30	27	25
Other Noncurrent Operating Assets	0.55	-	-	14	13	11
Total Liabilities & Shareholders' Equity	12	630	444	360	577	687
Total Liabilities	8.62	138	108	124	175	161
Total Current Liabilities	8.62	25	38	39	58	43
Accounts Payable	1.03	8.07	14	12	7.14	7.58
Accrued Expenses	1.05	17	25	28	51	35
Total Noncurrent Liabilities	0.00	113	70	85	117	118
Long-Term Debt	0.00	76	70	76	109	110
Other Noncurrent Operating Liabilities	0.00	38	0.00	8.92	8.32	7.60
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-22	492	336	236	402	527
Total Preferred & Common Equity	0.00	492	336	236	402	527
Total Common Equity	-22	492	336	236	402	527
Common Stock	-22	877	940	988	1,386	1,710
Retained Earnings	0.00	-386	-602	-753	-989	-1,186
Accumulated Other Comprehensive Income / (Loss)	0.00	0.69	-1.50	1.49	4.21	2.71

This table presents Centessa Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025
Total Assets	479	404	393	377	328	399	610	528	492	448
Total Current Assets	477	384	350	332	284	356	568	348	300	308
Cash & Equivalents	445	260	145	171	118	127	395	105	44	51
Short-Term Investments	-	86	158	110	112	167	123	179	206	195
Prepaid Expenses	12	18	20	23	18	19	16	14	8.94	12
Current Deferred & Refundable Income Taxes	20	20	27	28	36	42	34	50	41	49
Plant, Property, & Equipment, net	0.55	1.22	1.15	1.10	0.95	0.90	0.82	0.68	0.73	0.89
Total Noncurrent Assets	1.81	18	41	44	43	42	41	179	191	140
Long-Term Investments	-	-	-	-	-	-	-	140	153	103
Noncurrent Deferred & Refundable Income Taxes	-	-	27	30	29	29	27	26	25	25
Other Noncurrent Operating Assets	-	18	15	14	14	14	13	13	12	12
Total Liabilities & Shareholders' Equity	479	404	393	377	328	399	610	528	492	448
Total Liabilities	106	111	116	118	113	112	111	142	147	147
Total Current Liabilities	38	30	34	35	27	27	26	24	30	29
Accounts Payable	11	14	11	11	7.50	5.32	7.44	5.13	5.69	8.68
Accrued Expenses	27	15	23	24	20	21	19	19	24	20
Total Noncurrent Liabilities	68	81	82	83	86	85	84	117	118	118
Long-Term Debt	68	72	73	74	77	77	76	109	110	110
Other Noncurrent Operating Liabilities	0.04	9.31	9.15	9.02	8.77	8.63	8.47	8.14	7.97	7.79
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	373	293	277	259	215	287	499	386	345	302
Total Preferred & Common Equity	373	293	277	259	215	287	499	386	345	302
Total Common Equity	373	293	277	259	215	287	499	386	345	302
Common Stock	933	946	953	975	1,005	1,120	1,374	1,399	1,409	1,419
Retained Earnings	-559	-653	-677	-716	-791	-835	-877	-1,015	-1,065	-1,120
Accumulated Other Comprehensive Income / (Loss)	-1.70	-0.60	0.95	0.78	1.62	1.60	2.10	2.08	1.59	2.60

This table displays calculated financial ratios and metrics derived from Centessa Pharmaceuticals' official financial filings.

Metric	2019	2020	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	-	-	-	-	-	134,447,836.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	134,447,836.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-1.48
Growth Metrics	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	-100.00%	0.00%
EBITDA Growth	0.00%	-108.11%	0.00%	16.15%	-14.72%	-0.45%
EBIT Growth	0.00%	-107.86%	0.00%	15.82%	-14.73%	-1.01%
NOPAT Growth	0.00%	-106.61%	0.00%	19.31%	-17.38%	-3.30%
Net Income Growth	0.00%	-110.69%	0.00%	30.12%	-56.04%	16.21%
EPS Growth	0.00%	0.00%	0.00%	32.03%	-31.21%	29.13%
Operating Cash Flow Growth	0.00%	-82.49%	0.00%	20.05%	11.41%	-36.44%
Free Cash Flow Firm Growth	0.00%	0.00%	0.00%	0.00%	32.50%	-55.66%
Invested Capital Growth	0.00%	0.00%	0.00%	699.00%	-48.90%	111.35%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-100.00%	0.00%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	3.21%	-26.69%	5.30%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	3.08%	-26.52%	4.74%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	3.62%	-24.37%	2.86%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	4.02%	-46.19%	18.61%
EPS Q/Q Growth	0.00%	0.00%	0.00%	4.27%	-34.64%	23.16%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%	11.34%	-9.02%	-7.19%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	3.27%	-13.68%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	6.43%	-49.80%	-4.04%
Profitability Metrics	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	100.00%	0.00%	100.00%
EBITDA Margin	0.00%	0.00%	0.00%	-2,566.77%	0.00%	-1,351.37%
Operating Margin	0.00%	0.00%	0.00%	-2,499.39%	0.00%	-1,384.61%
EBIT Margin	0.00%	0.00%	0.00%	-2,578.59%	0.00%	-1,365.21%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	-2,204.65%	0.00%	-1,316.88%
Tax Burden Percent	100.00%	100.00%	99.66%	85.78%	101.22%	100.93%
Interest Burden Percent	102.28%	103.68%	103.35%	99.68%	114.88%	95.57%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	-384.73%	0.00%	-329.90%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	-372.50%	0.00%	-317.49%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	331.94%	0.00%	287.35%
Return on Equity (ROE)	0.00%	-344.19%	-52.24%	-52.79%	-73.93%	-42.55%
Cash Return on Invested Capital (CROIC)	0.00%	-1,175.70%	0.00%	-540.24%	-271.56%	-401.43%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	-43.93%	0.00%	-32.39%
Return on Assets (ROA)	0.00%	0.00%	0.00%	-37.56%	0.00%	-31.25%
Return on Common Equity (ROCE)	0.00%	2,491.21%	-52.24%	-52.79%	-73.93%	-42.55%
Return on Equity Simple (ROE_SIMPLE)	0.00%	0.00%	-64.32%	-63.95%	-58.71%	0.00%
Net Operating Profit after Tax (NOPAT)	-3.54	-7.31	-149	-120	-141	-145
NOPAT Margin	0.00%	0.00%	0.00%	-1,749.57%	0.00%	-969.23%
Net Nonoperating Expense Percent (NNEP)	0.00%	-419.38%	-20.54%	-12.23%	-34.30%	-12.41%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-38.44%	-27.57%	-22.82%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	784.05%	0.00%	336.45%
R&D to Revenue	0.00%	0.00%	0.00%	1,815.34%	0.00%	1,148.16%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	2,599.39%	0.00%	1,484.61%
Earnings before Interest and Taxes (EBIT)	-4.95	-10	-210	-177	-203	-205
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-4.94	-10	-210	-176	-202	-203
Valuation Ratios	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.86	3.24	4.78	6.44
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.86	3.24	4.78	6.44
Price to Revenue (P/Rev)	0.00	0.00	0.00	111.71	0.00	226.28
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	216.24	0.00	10.56	54.55	48.93
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	85.32	0.00	195.15
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-
Debt to Equity	0.00	1.82	0.21	0.32	0.27	0.21
Long-Term Debt to Equity	0.00	0.00	0.21	0.32	0.27	0.21
Financial Leverage	0.00	-0.52	-0.98	-0.89	-0.87	-0.91
Leverage Ratio	0.00	3.78	1.30	1.41	1.47	1.36
Compound Leverage Factor	0.00	3.92	1.34	1.40	1.69	1.30
Debt to Total Capital	0.00%	64.49%	17.19%	24.27%	21.34%	17.28%
Short-Term Debt to Total Capital	0.00%	64.49%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	17.19%	24.27%	21.34%	17.28%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	292.50%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	-257.00%	82.81%	75.73%	78.66%	82.72%
Debt to EBITDA	0.00	-0.55	-0.33	-0.43	-0.54	-0.54
Net Debt to EBITDA	0.00	0.16	1.54	1.03	1.85	2.30
Long-Term Debt to EBITDA	0.00	0.00	-0.33	-0.43	-0.54	-0.54
Debt to NOPAT	0.00	-0.77	-0.47	-0.63	-0.77	-0.76
Net Debt to NOPAT	0.00	0.22	2.18	1.51	2.65	3.21
Long-Term Debt to NOPAT	0.00	0.00	-0.47	-0.63	-0.77	-0.76
Altman Z-Score	0.00	18.25	-0.77	0.10	4.00	9.87
Noncontrolling Interest Sharing Ratio	0.00%	823.79%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-
Current Ratio	0.00	1.30	11.42	8.00	9.25	8.57
Quick Ratio	0.00	0.84	10.27	6.51	8.31	6.86
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-8.81	0.00	-168	-114	-177
Operating Cash Flow to CapEx	0.00%	0.00%	-17,638.17%	-94,876.92%	-417,808.82%	-52,241.78%
Free Cash Flow to Firm to Interest Expense	0.00	-28.41	0.00	-17.00	-2.57	-15.44
Operating Cash Flow to Interest Expense	-49.36	-34.29	-27.56	-16.19	-3.21	-16.91
Operating Cash Flow Less CapEx to Interest Expense	-49.36	-34.29	-27.72	-16.20	-3.22	-16.95
Efficiency Ratios	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.02	0.00	0.02
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	6.21	0.00	19.34
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	0.00	1.50	6.93	55	28	60
Invested Capital Turnover	0.00	0.00	0.00	0.22	0.00	0.34
Increase / (Decrease) in Invested Capital	0.00	1.50	0.00	48	-27	32
Enterprise Value (EV)	0.00	324	-34	585	1,544	2,927
Market Capitalization	300	300	290	766	1,917	3,394
Book Value per Share	$0.00	($1.49)	$3.55	$2.42	$3.05	$3.92
Tangible Book Value per Share	$0.00	($1.49)	$3.55	$2.42	$3.05	$3.92
Total Capital	0.00	8.73	406	312	510	637
Total Debt	0.00	5.63	70	76	109	110
Total Long-Term Debt	0.00	0.00	70	76	109	110
Net Debt	0.00	-1.60	-324	-181	-373	-467
Capital Expenditures (CapEx)	0.00	0.00	1.14	0.17	0.03	0.37
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	0.95	5.77	19	-3.77	30
Debt-free Net Working Capital (DFNWC)	0.00	8.17	399	276	478	325
Net Working Capital (NWC)	0.00	2.55	399	276	478	325
Net Nonoperating Expense (NNE)	1.52	3.36	68	31	95	52
Net Nonoperating Obligations (NNO)	0.00	-1.60	-329	-181	-373	-467
Total Depreciation and Amortization (D&A)	0.01	0.00	0.13	0.81	0.94	2.08
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	279.56%	0.00%	202.40%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	4,023.16%	0.00%	2,166.27%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	4,023.16%	0.00%	2,166.27%
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($2.31)	($1.57)	($2.06)	($1.46)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	93.40M	96.18M	114.47M	135.72M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($2.31)	($1.57)	($2.06)	($1.46)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	93.40M	96.18M	114.47M	135.72M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	94.96M	100.31M	133.18M	154.57M
Normalized Net Operating Profit after Tax (NOPAT)	-3.54	-7.31	-149	-120	-141	-145
Normalized NOPAT Margin	0.00%	0.00%	0.00%	-1,749.57%	0.00%	-969.23%
Pre Tax Income Margin	0.00%	0.00%	0.00%	-2,570.28%	0.00%	-1,304.75%
Debt Service Ratios	-	-	-	-	-	-
EBIT to Interest Expense	-41.93	-33.18	-28.85	-17.84	-4.59	-17.87
NOPAT to Interest Expense	-29.98	-23.57	-20.42	-12.10	-3.19	-12.69
EBIT Less CapEx to Interest Expense	-41.93	-33.18	-29.00	-17.86	-4.59	-17.90
NOPAT Less CapEx to Interest Expense	-29.98	-23.57	-20.57	-12.12	-3.19	-12.72
Payout Ratios	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Centessa Pharmaceuticals' official financial filings.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	134,447,836.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	134,447,836.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-0.49
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	23.35%	20.12%	13.99%	25.43%	9.77%	-2.06%	-118.70%	21.84%	-15.95%	-29.61%	13.37%
EBIT Growth	23.01%	19.71%	13.48%	25.08%	9.72%	-2.04%	-117.85%	20.93%	-16.51%	-30.09%	12.96%
NOPAT Growth	31.27%	17.99%	15.44%	26.16%	6.46%	-15.41%	-112.01%	14.72%	-24.27%	-15.91%	8.19%
Net Income Growth	61.51%	28.26%	14.68%	24.98%	-76.07%	-10.14%	-202.22%	31.31%	-14.90%	-28.96%	40.57%
EPS Growth	62.32%	29.82%	15.56%	28.30%	-53.85%	7.50%	-139.47%	47.37%	5.00%	-10.81%	48.35%
Operating Cash Flow Growth	26.41%	4.34%	39.78%	22.06%	7.90%	42.80%	-37.84%	-53.53%	44.67%	-172.63%	-30.39%
Free Cash Flow Firm Growth	2.59%	-45.52%	0.00%	-59.19%	30.68%	57.05%	65.63%	55.63%	62.41%	-18.45%	-216.30%
Invested Capital Growth	1,661.18%	1,040.36%	699.00%	231.61%	48.17%	8.34%	-48.90%	14.26%	-26.66%	10.57%	111.35%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	-100.00%	0.00%	0.00%	0.00%	0.00%	-100.00%	0.00%	0.00%
EBITDA Q/Q Growth	3.64%	13.79%	14.02%	-4.40%	-16.59%	2.49%	-84.26%	62.69%	-72.96%	-9.00%	-23.16%
EBIT Q/Q Growth	3.34%	13.72%	13.92%	-4.36%	-16.47%	2.48%	-83.78%	62.12%	-71.63%	-8.89%	-22.97%
NOPAT Q/Q Growth	3.80%	14.48%	12.51%	-2.59%	-21.86%	-5.51%	-60.72%	58.73%	-77.58%	1.58%	-27.30%
Net Income Q/Q Growth	50.93%	-55.30%	4.69%	-3.28%	-15.17%	2.85%	-161.54%	76.52%	-92.63%	-9.03%	-20.54%
EPS Q/Q Growth	50.94%	-53.85%	5.00%	0.00%	-5.26%	7.50%	-145.95%	78.02%	-90.00%	-7.89%	-14.63%
Operating Cash Flow Q/Q Growth	7.89%	15.14%	16.96%	-20.08%	-8.83%	47.29%	-100.10%	-33.75%	60.78%	-159.72%	4.30%
Free Cash Flow Firm Q/Q Growth	-78.23%	-11.92%	14.75%	6.39%	22.39%	30.65%	31.78%	-20.85%	34.25%	-118.53%	-82.16%
Invested Capital Q/Q Growth	148.60%	12.37%	6.43%	11.54%	11.08%	-17.84%	-49.80%	149.40%	-28.70%	23.87%	-4.04%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	100.00%	0.00%	0.00%	0.00%	0.00%	100.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	-522.54%	0.00%	0.00%	0.00%	0.00%	-194.81%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	-513.32%	0.00%	0.00%	0.00%	0.00%	-205.18%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	-526.13%	0.00%	0.00%	0.00%	0.00%	-198.34%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	-537.53%	0.00%	0.00%	0.00%	0.00%	-174.23%	0.00%	0.00%	0.00%
Tax Burden Percent	50.85%	93.19%	103.21%	101.28%	101.64%	101.45%	100.95%	105.65%	101.57%	100.30%	99.22%
Interest Burden Percent	100.81%	99.02%	98.99%	99.84%	98.37%	98.17%	140.40%	83.15%	97.07%	98.43%	97.54%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	-79.02%	0.00%	0.00%	0.00%	0.00%	-32.55%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	-74.23%	0.00%	0.00%	0.00%	0.00%	-30.59%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	66.15%	0.00%	0.00%	0.00%	0.00%	23.86%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-49.57%	-49.79%	-12.87%	0.00%	0.00%	0.00%	-73.93%	-8.69%	0.00%	0.00%	0.00%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-540.24%	-383.25%	-228.15%	-216.71%	-271.56%	-220.32%	-212.15%	-262.13%	-401.43%
Operating Return on Assets (OROA)	0.00%	0.00%	-8.96%	0.00%	0.00%	0.00%	0.00%	-6.95%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	-9.16%	0.00%	0.00%	0.00%	0.00%	-6.11%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-49.57%	-49.79%	-12.87%	0.00%	0.00%	0.00%	-73.93%	-8.69%	0.00%	0.00%	0.00%
Return on Equity Simple (ROE_SIMPLE)	-62.42%	-60.69%	0.00%	-64.33%	-54.83%	-32.31%	0.00%	-57.95%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-33	-28	-25	-25	-31	-32	-52	-22	-38	-38	-48
NOPAT Margin	0.00%	0.00%	-359.33%	0.00%	0.00%	0.00%	0.00%	-143.63%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	2.48%	-3.59%	-4.79%	-5.97%	-5.81%	-3.10%	-21.34%	-1.96%	-4.71%	-5.06%	-4.34%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-7.89%	-	-	-	-10.23%	-4.35%	-8.42%	-9.15%	-7.52%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	179.70%	0.00%	0.00%	0.00%	0.00%	82.23%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	433.62%	0.00%	0.00%	0.00%	0.00%	222.95%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	613.32%	0.00%	0.00%	0.00%	0.00%	305.18%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-49	-42	-36	-38	-44	-43	-79	-30	-51	-56	-68
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-48	-42	-36	-37	-44	-43	-78	-29	-51	-55	-68
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.13	2.41	3.24	5.25	3.45	3.72	4.78	4.95	5.09	10.79	6.44
Price to Tangible Book Value (P/TBV)	2.13	2.41	3.24	5.25	3.45	3.72	4.78	4.95	5.09	10.79	6.44
Price to Revenue (P/Rev)	0.00	0.00	111.71	164.71	144.27	271.25	0.00	127.53	117.10	216.90	226.28
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	7.75	8.03	10.56	15.79	11.22	25.11	54.55	22.63	29.04	48.34	48.93
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	85.32	142.33	112.41	206.65	0.00	106.49	97.46	200.95	195.15
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.27	0.29	0.32	0.36	0.27	0.15	0.27	0.28	0.32	0.36	0.21
Long-Term Debt to Equity	0.27	0.29	0.32	0.36	0.27	0.15	0.27	0.28	0.32	0.36	0.21
Financial Leverage	-0.93	-0.93	-0.89	-0.84	-0.80	-0.86	-0.87	-0.78	-0.81	-0.85	-0.91
Leverage Ratio	1.31	1.35	1.41	1.44	1.40	1.30	1.47	1.42	1.41	1.32	1.36
Compound Leverage Factor	1.32	1.34	1.39	1.44	1.38	1.28	2.06	1.18	1.37	1.30	1.33
Debt to Total Capital	20.95%	22.20%	24.27%	26.30%	21.05%	13.17%	21.34%	22.05%	24.10%	26.69%	17.28%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	20.95%	22.20%	24.27%	26.30%	21.05%	13.17%	21.34%	22.05%	24.10%	26.69%	17.28%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	79.05%	77.80%	75.73%	73.70%	78.95%	86.83%	78.66%	77.95%	75.90%	73.31%	82.72%
Debt to EBITDA	-0.38	-0.41	-0.43	-0.47	-0.48	-0.48	-0.54	-0.56	-0.54	-0.51	-0.54
Net Debt to EBITDA	1.20	1.14	1.03	0.94	1.38	2.78	1.85	1.63	1.46	1.12	2.30
Long-Term Debt to EBITDA	-0.38	-0.41	-0.43	-0.47	-0.48	-0.48	-0.54	-0.56	-0.54	-0.51	-0.54
Debt to NOPAT	-0.56	-0.59	-0.63	-0.69	-0.70	-0.67	-0.77	-0.80	-0.76	-0.73	-0.76
Net Debt to NOPAT	1.76	1.67	1.51	1.38	2.01	3.91	2.65	2.30	2.04	1.60	3.21
Long-Term Debt to NOPAT	-0.56	-0.59	-0.63	-0.69	-0.70	-0.67	-0.77	-0.80	-0.76	-0.73	-0.76
Altman Z-Score	1.18	1.10	1.39	3.20	3.02	8.92	4.71	5.99	4.48	10.18	10.52
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	10.35	9.51	8.00	10.37	13.29	21.52	9.25	14.37	10.12	10.57	8.57
Quick Ratio	8.96	8.05	6.51	8.39	11.02	19.63	8.31	11.76	8.44	8.45	6.86
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-77	-86	-73	-68	-53	-37	-25	-30	-20	-44	-79
Operating Cash Flow to CapEx	-440,620.00%	-86,958.14%	-110,892.86%	0.00%	0.00%	-62,908.82%	0.00%	0.00%	0.00%	-24,919.66%	-507,336.36%
Free Cash Flow to Firm to Interest Expense	-31.27	-33.74	-28.44	-27.05	-21.03	-14.40	-0.69	-10.55	-6.92	-15.09	-28.30
Operating Cash Flow to Interest Expense	-17.98	-14.72	-12.08	-14.74	-16.07	-8.36	-1.17	-19.90	-7.79	-20.18	-19.87
Operating Cash Flow Less CapEx to Interest Expense	-17.99	-14.73	-12.09	-14.74	-16.07	-8.38	-1.17	-19.90	-7.79	-20.26	-19.88
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.02	0.02	0.02	0.01	0.00	0.04	0.03	0.03	0.02
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	6.21	6.31	6.69	7.13	0.00	18.37	18.34	17.49	19.34
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	46	52	55	62	69	56	28	71	50	62	60
Invested Capital Turnover	0.00	0.00	0.22	0.17	0.12	0.13	0.00	0.23	0.25	0.25	0.34
Increase / (Decrease) in Invested Capital	44	58	48	43	22	4.34	-27	8.81	-18	5.96	32
Enterprise Value (EV)	359	418	585	975	770	1,416	1,544	1,597	1,462	3,014	2,927
Market Capitalization	589	625	766	1,129	989	1,859	1,917	1,913	1,757	3,253	3,394
Book Value per Share	$2.91	$2.66	$2.42	$2.15	$2.54	$4.40	$3.05	$2.90	$2.58	$2.25	$3.92
Tangible Book Value per Share	$2.91	$2.66	$2.42	$2.15	$2.54	$4.40	$3.05	$2.90	$2.58	$2.25	$3.92
Total Capital	350	333	312	292	363	575	510	495	454	411	637
Total Debt	73	74	76	77	77	76	109	109	110	110	110
Total Long-Term Debt	73	74	76	77	77	76	109	109	110	110	110
Net Debt	-230	-207	-181	-153	-218	-443	-373	-316	-295	-239	-467
Capital Expenditures (CapEx)	0.01	0.04	0.03	0.00	0.00	0.03	0.00	0.00	0.00	0.23	0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)	13	16	19	27	34	24	-3.77	39	20	32	30
Debt-free Net Working Capital (DFNWC)	317	297	276	257	329	542	478	324	271	279	325
Net Working Capital (NWC)	317	297	276	257	329	542	478	324	271	279	325
Net Nonoperating Expense (NNE)	-8.03	11	12	13	13	10	59	4.59	12	17	18
Net Nonoperating Obligations (NNO)	-230	-207	-181	-153	-218	-443	-373	-316	-295	-239	-467
Total Depreciation and Amortization (D&A)	0.24	0.24	0.25	0.24	0.24	0.24	0.23	0.53	0.52	0.51	0.52
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	279.56%	392.00%	494.88%	343.05%	0.00%	260.07%	132.97%	215.59%	202.40%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	4,023.16%	3,750.78%	4,797.13%	7,908.33%	0.00%	2,156.77%	1,804.46%	1,857.02%	2,166.27%
Net Working Capital to Revenue	0.00%	0.00%	4,023.16%	3,750.78%	4,797.13%	7,908.33%	0.00%	2,156.77%	1,804.46%	1,857.02%	2,166.27%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.26)	($0.40)	($0.38)	($0.38)	($0.40)	($0.37)	($0.91)	($0.20)	($0.38)	($0.41)	($0.47)
Adjusted Weighted Average Basic Shares Outstanding	95.16M	96.65M	96.18M	99.89M	109.49M	116.25M	114.47M	133.03M	133.68M	134.16M	135.72M
Adjusted Diluted Earnings per Share	($0.26)	($0.40)	($0.38)	($0.38)	($0.40)	($0.37)	($0.91)	($0.20)	($0.38)	($0.41)	($0.47)
Adjusted Weighted Average Diluted Shares Outstanding	95.16M	96.65M	96.18M	99.89M	109.49M	116.25M	114.47M	133.03M	133.68M	134.16M	135.72M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	97.40M	97.63M	100.31M	113.04M	113.31M	131.85M	133.18M	133.62M	134.07M	134.45M	154.57M
Normalized Net Operating Profit after Tax (NOPAT)	-33	-28	-25	-25	-31	-32	-52	-22	-38	-38	-48
Normalized NOPAT Margin	0.00%	0.00%	-359.33%	0.00%	0.00%	0.00%	0.00%	-143.63%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	-520.84%	0.00%	0.00%	0.00%	0.00%	-164.92%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-19.81	-16.48	-14.03	-14.88	-17.36	-16.72	-2.15	-10.34	-17.70	-19.24	-24.35
NOPAT to Interest Expense	-13.43	-11.08	-9.58	-9.99	-12.19	-12.70	-1.43	-7.49	-13.27	-13.03	-17.07
EBIT Less CapEx to Interest Expense	-19.82	-16.50	-14.04	-14.88	-17.36	-16.73	-2.15	-10.34	-17.70	-19.32	-24.35
NOPAT Less CapEx to Interest Expense	-13.44	-11.09	-9.59	-9.99	-12.19	-12.72	-1.43	-7.49	-13.27	-13.11	-17.07
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Centessa Pharmaceuticals (CNTA) remains in a cash-burn, pre-revenue phase, but the 2025 quarters show a notable shift in liquidity thanks to equity financings. Here are 10 key takeaways from the last four years of quarterly statements, focused on the most relevant near-term drivers for retail investors.

In 2025 CNTA raised substantial capital via common-equity offerings in 2025 Q3 and 2025 Q4, delivering roughly $242.7M and $269.2M of gross proceeds, strengthening liquidity runway and the balance sheet.
Net financing cash flow in 2025 Q4 was strongly positive (about $283.4M), driven by the equity raises and enhancing near-term liquidity flexibility.
Investing activity in some 2025 quarters provided liquidity via sale/maturity of investments (Q3 2025: about $107.7M; Q4 2025: about $95.6M).
Topline growth is sporadic: CNTA posted about $15.0M in operating revenue in 2025 Q1, but many quarters show little to no revenue, keeping profitability elusive in the near term.
R&D and SG&A remain high in 2025 (Q4 2025: RD ~$54.5M; SG&A ~$14.0M; total operating expenses around $68.5M), driving substantial operating losses.
Net cash from continuing operating activities was negative in all 2025 quarters, indicating ongoing cash burn before financing activities.
Long-term debt sits around $109–110M through mid-2025, providing a modest liquidity cushion but not reducing near-term cash needs.
Equity issuance implies dilution risk for existing shareholders, a common feature for pre-revenue biotech financings intended to fund operations and pipeline development.
Net income to common shareholders remained negative across 2025 quarters (roughly -$38M in Q1, -$50–54M in later quarters, culminating around -$66M in 2025 Q4), with EPS consistently negative.
Investing activity in 2025 Q4 was substantial, including roughly $313.7M in purchases of investments, contributing to a large net cash outflow despite strong financing inflows.

05/06/26 07:45 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Centessa Pharmaceuticals' Financials

When does Centessa Pharmaceuticals' fiscal year end?

According to the most recent income statement we have on file, Centessa Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

How has Centessa Pharmaceuticals' net income changed over the last 5 years?

Centessa Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$197.53 million in 2025, rising from -$5.06 million in 2019. The previous period was -$235.76 million in 2024. Find out what analysts predict for Centessa Pharmaceuticals in the coming months.

What is Centessa Pharmaceuticals' operating income?

Centessa Pharmaceuticals' total operating income in 2025 was -$207.69 million, based on the following breakdown:

Total Gross Profit: $15 million
Total Operating Expenses: $222.69 million

How has Centessa Pharmaceuticals' revenue changed over the last 5 years?

Over the last 5 years, Centessa Pharmaceuticals' total revenue changed from $0.00 in 2019 to $15 million in 2025, a change of 1,500,000,000.0%.

How much debt does Centessa Pharmaceuticals have?

Centessa Pharmaceuticals' total liabilities were at $160.63 million at the end of 2025, a 8.3% decrease from 2024, and a 1,763.7% increase since 2020.

How much cash does Centessa Pharmaceuticals have?

In the past 5 years, Centessa Pharmaceuticals' cash and equivalents has ranged from $7.23 million in 2020 to $595.08 million in 2021, and is currently $61.30 million as of their latest financial filing in 2025.

How has Centessa Pharmaceuticals' book value per share changed over the last 5 years?

Over the last 5 years, Centessa Pharmaceuticals' book value per share changed from 0.00 in 2019 to 3.92 in 2025, a change of 391.9%.

Related Companies

Financial statements for NASDAQ:CNTA last updated on 4/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Centessa Pharmaceuticals (CNTA) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Centessa Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Centessa Pharmaceuticals (CNTA) Financials

Annual Income Statements for Centessa Pharmaceuticals

Quarterly Income Statements for Centessa Pharmaceuticals

Annual Cash Flow Statements for Centessa Pharmaceuticals

Quarterly Cash Flow Statements for Centessa Pharmaceuticals

Annual Balance Sheets for Centessa Pharmaceuticals

Quarterly Balance Sheets for Centessa Pharmaceuticals

Annual Metrics And Ratios for Centessa Pharmaceuticals

Quarterly Metrics And Ratios for Centessa Pharmaceuticals

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Centessa Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools